Entity Details

Primary name CFAH_HUMAN
Entity type UniProt
Source Source Link

Details

AccessionP08603
EntryNameCFAH_HUMAN
FullNameComplement factor H
TaxID9606
Evidenceevidence at protein level
Length1231
SequenceStatuscomplete
DateCreated1988-08-01
DateModified2021-06-02

Ontological Relatives

GenesCFH

GO terms

Show/Hide Table
GOName
GO:0005576 extracellular region
GO:0005615 extracellular space
GO:0006956 complement activation
GO:0006957 complement activation, alternative pathway
GO:0008201 heparin binding
GO:0016032 viral process
GO:0030449 regulation of complement activation
GO:0042802 identical protein binding
GO:0043395 heparan sulfate proteoglycan binding
GO:0070062 extracellular exosome
GO:0072562 blood microparticle
GO:1903659 regulation of complement-dependent cytotoxicity

Subcellular Location

Show/Hide Table
Subcellular Location
Secreted

Domains

Show/Hide Table
DomainNameCategoryType
IPR000436 Sushi/SCR/CCP domainDomainDomain
IPR035976 Sushi/SCR/CCP superfamilyFamilyHomologous superfamily

Diseases

Show/Hide Table
Disease IDSourceNameDescription
609814 OMIMComplement factor H deficiency (CFHD)A disorder that can manifest as several different phenotypes, including asymptomatic, recurrent bacterial infections, and renal failure. Laboratory features usually include decreased serum levels of factor H, complement component C3, and a decrease in other terminal complement components, indicating activation of the alternative complement pathway. It is associated with a number of renal diseases with variable clinical presentation and progression, including membranoproliferative glomerulonephritis and atypical hemolytic uremic syndrome. The disease is caused by variants affecting the gene represented in this entry.
235400 OMIMHemolytic uremic syndrome atypical 1 (AHUS1)An atypical form of hemolytic uremic syndrome. It is a complex genetic disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, renal failure and absence of episodes of enterocolitis and diarrhea. In contrast to typical hemolytic uremic syndrome, atypical forms have a poorer prognosis, with higher death rates and frequent progression to end-stage renal disease. Disease susceptibility is associated with variants affecting the gene represented in this entry. Other genes may play a role in modifying the phenotype.
610698 OMIMMacular degeneration, age-related, 4 (ARMD4)A form of age-related macular degeneration, a multifactorial eye disease and the most common cause of irreversible vision loss in the developed world. In most patients, the disease is manifest as ophthalmoscopically visible yellowish accumulations of protein and lipid that lie beneath the retinal pigment epithelium and within an elastin-containing structure known as Bruch membrane. Disease susceptibility is associated with variants affecting the gene represented in this entry.
126700 OMIMBasal laminar drusen (BLD)Drusen are extracellular deposits that accumulate below the retinal pigment epithelium on Bruch membrane. Basal laminar drusen refers to an early adult-onset drusen phenotype that shows a pattern of uniform small, slightly raised yellow subretinal nodules randomly scattered in the macula. In later stages, these drusen often become more numerous, with clustered groups of drusen scattered throughout the retina. In time these small basal laminar drusen may expand and ultimately lead to a serous pigment epithelial detachment of the macula that may result in vision loss. The gene represented in this entry is involved in disease pathogenesis.

Drugs

Show/Hide Table
DrugNameSourceType
DB01593 ZincDrugbanksmall molecule
DB09130 CopperDrugbanksmall molecule
DB14487 Zinc acetateDrugbanksmall molecule
DB14533 Zinc chlorideDrugbanksmall molecule
DB14548 Zinc sulfate, unspecified formDrugbanksmall molecule